eagle-i The University of PennsylvaniaThe University of Pennsylvania
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Biological assay development for screening experiments

eagle-i ID

http://eagle-i.itmat.upenn.edu/i/0000013f-8b3d-738d-a468-831a80000000

Resource Type

  1. Analysis service

Properties

  1. Fee for service
    Yes
  2. Resource Description
    "The overarching goal for Assay Development focuses on the timely delivery of robust and well validated biological assays ready for implementation in screening experiments. Users are encouraged to contact laboratory staff as early as possible and remain actively engaged throughout the entire process. The laboratory staff provide: • Expertise in cell biology, molecular biology, enzymology, biochemistry, pharmacology, and microbiology. • Facilities for propagation of bacteria, yeast, insect cells, mammalian cells, and viruses (i.e. baculovirus, retrovirus). • Expertise in expression and purification of recombinant proteins. • Equipment and expertise for maintenance, quality control and molecular characterization of normal and engineered cells for cell-based assays under standard biosafety containment up to and including BSL-2. • Experience with a variety of biochemical, cellular, immunological, and image based assays using an array of equipment compatible with bench scale or HTS scale experiments. <b>Guidelines to developing a miniaturized bioassay for High-throughput screening</b> The process of assay development includes the identification of assay types for screening and determination of structure-activity-relationships, development of assay reagents, optimization of assay parameters for signal intensity, signal window, and precision, adaptation to automation, scalability, and quantitative assessment of the assay's fitness for screening. Assay parameters to optimize assay's include sensitivity to enable identification of compounds with low-potentcy, precision of biological response between wells and plates, accuracy of positive and negative control compounds with known pharmacology towards the intended target, and economic feasibility."
  3. Service Fee URL
    http://www.wistar.org/our-science/shared-facilities/molecular-screening-facility/cost-structure
  4. Service Provided by
    Molecular Screening Facility (Wistar)
  5. Website(s)
    http://www.wistar.org/our-science/shared-facilities/molecular-screening-facility/services
  6. Related Technique
    Compound library screening
  7. Related Technique
    RNAi screening
  8. Related Technique
    Small molecule screening
 
RDFRDF
 
Provenance Metadata About This Resource Record
  1. workflow state
    Published
  2. contributor
    fcoldren
  3. created
    2013-06-28T10:45:56.610-04:00
  4. creator
    fcoldren
  5. modified
    2013-07-02T10:50:15.199-04:00

Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016